Literature DB >> 19641470

Nontuberculous mycobacteria infections in immunocompromised patients: single institution experience.

Michael C Wei1, Niaz Banaei, Mitchell A Yakrus, Tracey Stoll, Kathleen M Gutierrez, Rajni Agarwal.   

Abstract

Disseminated infection due to nontuberculous Mycobacterium (NTM) species is rare in pediatrics. Here we report 6 infections affecting 5 patients at a single institution in an immunocompromised population of pediatric oncology and stem cell transplant recipients. The patients presented within a 1-year period with catheter-associated bacteremia. New pulmonary nodules were noted in 4 of the 5 patients. All of the infections were due to rapidly growing NTM. Patients were successfully treated with removal of the infected catheter and combination antibiotic therapy. There are currently no consensus guidelines for treatment of NTM infections in this population, and a therapeutic approach is presented here.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641470     DOI: 10.1097/MPH.0b013e31819ed274

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

Review 1.  Infections Caused by Rapidly Growing Mycobacteria spp in Children and Adolescents With Cancer.

Authors:  Nopporn Apiwattankul; Patricia M Flynn; Randall T Hayden; Elisabeth E Adderson
Journal:  J Pediatric Infect Dis Soc       Date:  2014-05-07       Impact factor: 3.164

2.  Use of MALDI-TOF MS for Identification of Nontuberculous Mycobacterium Species Isolated from Clinical Specimens.

Authors:  María Concepción Mediavilla-Gradolph; Inmaculada De Toro-Peinado; María Pilar Bermúdez-Ruiz; María de los Ángeles García-Martínez; María Ortega-Torres; Natalia Montiel Quezel-Guerraz; Begoña Palop-Borrás
Journal:  Biomed Res Int       Date:  2015-05-28       Impact factor: 3.411

Review 3.  Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation.

Authors:  Khalid Ahmed Al-Anazi; Asma M Al-Jasser; Waleed Khalid Al-Anazi
Journal:  Front Oncol       Date:  2014-11-10       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.